The global vaccines market is expected to grow at a CAGR of around 6.4% from forecast period 2019 to 2026 and to reach the market value of around US$ 55.2 billion by 2026.
Vaccine is a biological product that provides acquired immunity against a specific disease. It is generally prepared from killed or weaken disease causing microorganism, one of its surface proteins, or from its toxins. Vaccination is the most effective method to prevent infectious diseases. Polio, influenza, HPV vaccine, meningococcal, and dengue are some of the widely used vaccines across the world. Increasing infectious diseases, investment in research and development by market players, government and private organizations initiatives to increase awareness about vaccination, and entry of various vaccines in the market are the key driving factors of the market. According to the World Health Organization (WHO), immunization prevents about 2 to 3 million deaths each year from influenza, diphtheria, pertussis, tetanus, and measles. Furthermore, it can prevent additional 1.5 million deaths if vaccination coverage improves across the world.
Market Dynamics
Increase in vaccination as it is one of the best cost-effective method to avoid diseases, rising in an access in developing countries due to initiatives by WHO and UNICEF’s immunization programs, and introduction of vaccines against various regional diseases are some of the driving factors of the vaccines market. Favorable reimbursement, growing awareness about vaccination, and investment by market players to introduce vaccines in the market are also positively impact the market growth. According to the recent data published by the WHO, measles mortality decreased by 80% across the world. In 2018, about 86% infants received 3 doses of DTP3 vaccine, protecting them from infectious diseases. Similarly, HPV vaccine was introduced in about 90 countries till 2018. However, high development cost and stringent regulations for commercialization of vaccines are the key restraining factors of the vaccines market. Hence, high cost of product may hamper its access in low and middle income countries. According to the WHO, every year about more than 10 million children die before they reach their 5th birthdays in low and middle income countries.
Based on technology, the vaccines market has been segmented into conjugate vaccines, inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines. The conjugate vaccine segment held the largest share in the market due to long lasting protection and greater ability to give protection to toddlers and infants. Conjugate vaccine has a combination of weak and strong antigen as a carrier so that immune system gives strong response to weak antigen.
Pediatric vaccines accounted for the maximum share of the market in 2018. This can be attributed to large targeted population, government initiatives to increase children vaccination, and increasing awareness about vaccination schedules. Adult vaccine segment is also expecting significant growth in coming years due to rising awareness about regular health checkup and vaccination after 40 years of age.
Based on the route of administration, the market has been segmented into intramuscular & subcutaneous, oral, and others. The intramuscular segment accounted for the maximum share of the market in 2018 and is expected to maintain its dominance during the forecasts period as the route avoid adverse local effect of vaccine.
The market research study on “Vaccines Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”, offers a detailed insight on the global vaccines market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global vaccines market, its technology, disease indication, type, patient type, rote of administration, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global vaccines market size and segment markets by technology, disease indication, type, type of patient, rote of administration, and geography along with the information on companies operating in the market. The vaccines market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market size for different segments has been covered under the scope of the report.
The players profiled in the vaccines market report include Astellas Pharma Inc., Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, MedImmune, LLC, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation. The key players of the industry are involved in R&D activities, commercialization of products, and mergers & collaborations to enhance their footprints in the industry. For instance, in February 2019, Bharat Biotech acquired Chiron Behring Vaccines Pvt. Ltd. from GlaxoSmithKline Asia. Chiron is one of the largest manufactures of rabies vaccines across the world. The acquisition is helping Bharat biotech to strengthen its product portfolio.
Market Segmentation
Market By Technology
- Conjugate Vaccines
- Inactivated Vaccines
- Live Attenuated Vaccines,
- Toxoid Vaccines
- Recombinant Vaccines
By Indication
- Dengue
- DTP
- Hepatitis
- HPV
- Influenza
- Meningococcal
- MMR
- Pneumococcal
- Polio
- Rotavirus
- Varicella
By Type
By Route of Administration
- Intramuscular
- Subcutaneous
- Oral
- Others
By Type of Patient
Market By Geography
- North America
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Table Of Content
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Vaccine
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Vaccine Market By Technology
1.2.2.1. Global Vaccine Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.2.2. Global Vaccine Market Revenue Share By Technology in 2017
1.2.2.3. Conjugate Vaccines
1.2.2.4. Inactivated Vaccines
1.2.2.5. Live Attenuated Vaccines
1.2.2.6. Toxoid Vaccines
1.2.2.7. Recombinant Vaccines
1.2.3. Vaccine Market By Indication
1.2.3.1. Global Vaccine Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.3.2. Global Vaccine Market Revenue Share By Indication in 2017
1.2.3.3. Dengue
1.2.3.4. DTP
1.2.3.5. Hepatitis
1.2.3.6. HPV
1.2.3.7. Influenza
1.2.3.8. Meningococcal
1.2.3.9. MMR
1.2.3.10. Pneumococcal
1.2.3.11. Polio
1.2.3.12. Rotavirus
1.2.3.13. Varicella
1.2.4. Vaccine Market By Type
1.2.4.1. Global Vaccine Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.4.2. Global Vaccine Market Revenue Share By Type in 2017
1.2.4.3. Monovalent
1.2.4.4. Multivalent
1.2.5. Vaccine Market By Route of Administration
1.2.5.1. Global Vaccine Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.5.2. Global Vaccine Market Revenue Share By Route of Administration in 2017
1.2.5.3. Intramuscular
1.2.5.4. Subcutaneous
1.2.5.5. Oral
1.2.5.6. Others
1.2.6. Vaccine Market By Type of Patient
1.2.6.1. Global Vaccine Market Revenue and Growth Rate Comparison By Type of Patient (2015-2026)
1.2.6.2. Global Vaccine Market Revenue Share By Type of Patient in 2017
1.2.6.3. Children
1.2.6.4. Adult
1.2.7. Vaccine Market By Geography
1.2.7.1. Global Vaccine Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.7.2. North America Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.3. Europe Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.4. Asia-Pacific Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.5. Latin America Vaccine Market Revenue and Growth Rate (2015-2026)
1.2.7.6. Middle East and Africa (MEA) Vaccine Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Vaccine Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Vaccine Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Vaccine Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Vaccine Major Manufacturers in 2017
CHAPTER 4. Vaccine Market By Technology
4.1. Global Vaccine Revenue By Technology
4.2. Conjugate Vaccines
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Inactivated Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Live Attenuated Vaccines
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Toxoid Vaccines
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Recombinant Vaccines
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. Vaccine Market By Indication
5.1. Global Vaccine Revenue By Indication
5.2. Dengue
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. DTP
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Hepatitis
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. HPV
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Influenza
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Meningococcal
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. MMR
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Pneumococcal
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.10. Polio
5.10.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.10.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.11. Rotavirus
5.11.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.11.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.12. Varicella
5.12.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.12.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. Vaccine Market By Type
6.1. Global Vaccine Revenue By Type
6.2. Monovalent
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Multivalent
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. Vaccine Market By Route of Administration
7.1. Global Vaccine Revenue By Route of Administration
7.2. Intramuscular
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Subcutaneous
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Oral
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.5. Others
7.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 8. Vaccine Market By Type of Patient
8.1. Global Vaccine Revenue By Type of Patient
8.2. Children
8.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
8.3. Adult
8.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 9. North America Vaccine Market By Country
9.1. North America Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. North America Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. U.S.
9.3.1. U.S. Vaccine Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Canada
9.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 10. Europe Vaccine Market By Country
10.1. Europe Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Europe Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. UK
10.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. Germany
10.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. France
10.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.6. Spain
10.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.7. Rest of Europe
10.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 11. Asia-Pacific Vaccine Market By Country
11.1. Asia-Pacific Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Asia-Pacific Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. China
11.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Japan
11.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.5. India
11.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.6. Australia
11.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.7. South Korea
11.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.8. Rest of Asia-Pacific
11.8.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.8.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 12. Latin America Vaccine Market By Country
12.1. Latin America Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Latin America Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Brazil
12.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.4. Mexico
12.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.5. Rest of Latin America
12.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 13. MIDDLE EAST & AFRICA VACCINE MARKET BY COUNTRY
13.1. Middle East & Africa Vaccine Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Middle East & Africa Vaccine Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. GCC
13.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.4. South Africa
13.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.5. Rest of Middle East & Africa
13.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
CHAPTER 14. COMPANY PROFILE
14.1. Astellas Pharma Inc.
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Bavarian Nordic
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. CSL Limited
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Daiichi Sankyo Company, Limited
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Emergent BioSolutions, Inc.
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. GlaxoSmithKline plc
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Johnson & Johnson
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. MedImmune, LLC
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. Merck & Co., Inc.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Mitsubishi Tanabe Pharma Corporation
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
14.11. Others
14.11.1. Company Snapshot
14.11.2. Overview
14.11.3. Financial Overview
14.11.4. Product Portfolio
14.11.5. Key Developments
14.11.6. Strategies
CHAPTER 15. RESEARCH APPROACH
15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope
